22:58 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
21:55 , Oct 8, 2018 |  BC Extra  |  Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial...
23:43 , Feb 14, 2018 |  BC Extra  |  Preclinical News

Three targets in the same brain region could alleviate depression

A Zhejiang University team published a pair of papers in Nature suggesting ketamine works by modulating the firing of neurons in the lateral habenula, a brain region that controls reward signaling. The studies point to...
17:37 , Mar 30, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies identified calcium channel T-type and potassium channel inhibitors that could help treat glioblastoma. Screening of a library of ion channel blockers against primary human glioblastoma cell lines...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

Mibefradil dihydrochloride: Phase Ib started

Cavion said Yale University began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate 150-350 mg/day oral mibefradil given over 4 daily doses with hypofractionated radiation therapy for 17 days in about 24 adults with...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Company News

Tau Therapeutics, Xdynia deal

Tau Therapeutics and Xdynia merged to form Cavion LLC. In 2012, Tau launched Xdynia to develop calcium channel T-type inhibitors for neuropathic pain. Tau was developing calcium channel T-type antagonists to treat solid tumors. Cavion...
07:00 , Jun 23, 2014 |  BioCentury  |  Product Development

Nav(1.7)igating pain

Data reported by Convergence Pharmaceuticals Ltd. last week for CNV1014802 to treat trigeminal neuralgia gave the first Phase II evidence that systemic Nav1.7 blockers can treat pain safely and effectively. The data also lend further...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Aptiom eslicarbazepine acetate: Additional Phase III data

On the secondary endpoint of change from baseline in standardized seizure frequency during the 18-week, double-blind treatment period, eslicarbazepine led to a median reduction in seizure frequency of 30.9% in the 1,200 mg arm and...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

Z944: Phase Ib data

Data from 16 healthy volunteers in a double-blind, crossover, German Phase Ib trial showed that 3 dose levels of a single dose of oral Z944 each reduced overall peak-to-peak amplitude of LEPs in models of...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Clinical News

Eslicarbazepine acetate: Phase III data

The identical, double-blind Phase III Study 093-045 and Study 093-046 in patients 18 years and older with epilepsy who were not well controlled by antiepileptic drugs showed that conversion to once-daily eslicarbazepine as monotherapy met...